| Phase I | |
---|---|---|
No GERD | GERD | |
n = 3627 | n = 2101 | |
Demographics | ||
 Age, years | 59.0 (8.74) | 60.9 (8.38) |
 Female | 1668 (46%) | 1168 (56%) |
 African American | 1269 (35%) | 489 (23%) |
 Current smoker | 1928 (53%) | 862 (41%) |
 Pack-years | 40.9 (22.2) | 45.3 (25.4) |
 BMI, kg/m2 | 28.6 (6.0) | 29.9 (6.3) |
 Education beyond HS | 2348 (65%) | 1396 (66%) |
Spirometry | ||
 FEV1% predicted | 82 (23) | 77 (23) |
 FVC % predicted | 90 (17) | 87 (17) |
 FEV1/FVC | 0.70 (0.14) | 0.67 (0.15) |
GOLD stage | ||
 PRISm | 438 (12%) | 263 (13%) |
 GOLD 0 | 1826 (51%) | 851 (41%) |
 GOLD 1 | 321 (8.9%) | 182 (8.7%) |
 GOLD 2 | 626 (17%) | 483 (23%) |
 GOLD 3 | 309 (8.6%) | 258 (12%) |
 GOLD 4 | 86 (2.4%) | 55 (2.6%) |
Inhaled therapies | ||
 SABA | 776 (22%) | 763 (37%) |
 LABA | 57 (1.6%) | 85 (4.1%) |
 ICS | 137 (3.9%) | 144 (7.0%) |
 ICS/LABA | 438 (12%) | 460 (22%) |
 LAMA | 362 (10%) | 389 (19%) |
Quantitative CT chest | ||
 AWT-Pi10, mm | 2.2 (0.58) | 2.3 (0.58) |
 Airway wall area, % | 50 (8.3) | 50 (8.2) |
 Air trapping, % | 19 (17) | 22 (18) |
 Emphysema, % | 5.1 (8) | 6.4 (9.1) |
 Perc15 lung density, HU | 78 (22) | 76 (23) |
Clinical outcomes | ||
 Acute exacerbation | 499 (14%) | 563 (27%) |
 Severe exacerbation | 252 (6.9%) | 254 (12%) |
 Cough | 1126 (31%) | 815 (39%) |
 Phlegm | 1126 (31%) | 803 (38%) |
 Wheeze | 1380 (38%) | 1093 (52%) |
 SGRQ, total score | 14 (3.8, 32) | 25 (9.3, 45) |
 mMRC ≥2 | 1086 (30%) | 949 (45%) |
 6-MWD, feet | 1448 (368.8) | 1369 (370.4) |